Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel

[Introduction] For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the...

Full description

Bibliographic Details
Authors: Bernardo, Miquel, Díaz-Marsá, Marina, González-Pinto, Ana, Martín Carrasco, Manuel, Pérez-Solá, Víctor, Sáiz, Pilar A., Vieta, Eduard, Torrens, Marta, Arango, Celso, Crespo-Facorro, Benedicto
Format: article
Status:Published version
Publication Date:2025
Country:España
Institution:Consejo Superior de Investigaciones Científicas (CSIC)
Repository:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/391421
Online Access:http://hdl.handle.net/10261/391421
https://api.elsevier.com/content/abstract/scopus_id/85214271444
Access Level:Open access
Keyword:Antipsychotic
First-episode psychosis
Lurasidone
Schizophrenia
Tolerability
Treatment
Description
Summary:[Introduction] For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low-dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13–17 years). The efficacy and tolerability of lurasidone have been demonstrated in both antipsychotic-naïve and previously treated patients.

Similar Items